Company Overview and News

 
BSET / Bassett Furniture Industries, Inc. FORM SD

2018-05-17 sec.gov
bset20180516_sd.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

1
Wayfair Needs to Prove This Isn't as Good as It Gets - Bloomberg

2018-05-02 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Hooker Furniture: Q4 And The Story, Enough To Stick Around

2018-04-24 seekingalpha
Hooker's Q4 wasn't spectacular, but it was good enough to close a solid fiscal 2018 (ending January).

1
10 Stocks to Short as China Hits Back

2018-04-13 investorplace
U.S. equity markets have been much choppier so far in 2018, to say the least. Volatility has doubled. February saw the first market correction in two years. And since then, U.S. stocks have swung back and forth, with a number of big one-day moves along the way.

 
Why Bassett Furniture (BSET) Could Be Positioned for a Slump

2018-04-10 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. One such stock that you may want to consider dropping is Bassett Furniture Industries, Incorporated (BSET - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.

 
BSET / Bassett Furniture Industries, Inc. / GAMCO INVESTORS, INC. ET AL - null (Activist Investment)

2018-04-02 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
BSET / Bassett Furniture Industries, Inc. / GAMCO INVESTORS, INC. ET AL - null (Activist Investment)

2018-04-02 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

1
Don’t Get in the Way of Restoration Hardware Holdings, Inc (RH) Stock

2018-03-28 investorplace
Restoration Hardware Holdings, Inc (NYSE:RH) has become one of the biggest battleground stocks in the market. Heading into the company’s fiscal fourth-quarter earnings report on Tuesday afternoon, some 41% of the float of RH stock was sold short.

 
BSET / Bassett Furniture Industries, Inc. FORM 10-Q (Quarterly Report)

2018-03-28 sec.gov
bset20180224_10q.htm UNITED STATES

 
BSET / Bassett Furniture Industries, Inc. FORM 8-K (Current Report)

2018-03-28 sec.gov
bset20180327_8k.htm UNITED STATES

 
BSET / Bassett Furniture Industries, Inc. FORM 8-K (Current Report)

2018-03-14 sec.gov
bset20180313c_8k.htm UNITED STATES

 
Lay-Z-Boy: Strong Headline Numbers, But Key Issues Linger

2018-03-13 seekingalpha
A strong Q3 sent shares of LZB back above $30. LZB now trades at a 12% premium to peers.

 
BSET / Bassett Furniture Industries, Inc. FORM 8-K (Current Report)

2018-03-13 sec.gov
bset20180313b_8k.htm UNITED STATES

 
BSET / Bassett Furniture Industries, Inc. FORM 8-K (Current Report)

2018-03-08 sec.gov
bset20180308_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 070203104